CRELD1, Recombinant, Human, aa30-362, His-Tag (Cysteine-rich with EGF-like Domain Protein 1, AVSD2, CIRRIN)

Catalog No : USB-145785
682.78€
0.00€

Shipping cost plus VAT not included , delivery in 7-14 business days

Product name CRELD1, Recombinant, Human, aa30-362, His-Tag (Cysteine-rich with EGF-like Domain Protein 1, AVSD2, CIRRIN)
Catalog No USB-145785
Supplier’s Catalog No 145785
Supplier US Biologicals
Source antigen Recombinant, NS0 cells
Reactivity
Cross reactivity
Applications
Molecular weight 5055
Storage -20°C
Other names
Grade Highly Purified
Purity ~95% (SDS-PAGE)
Form Supplied as a lyophilized powder in PBS. Reconstitute in 500ul sterile PBS.
Reactivity life 6 months
Note For reserch purpose only
Purity ~95% (SDS-PAGE)
Description Cysteine-rich with EGF-like domain protein 1 (CRELD1) is an ~50kD transmembrane glycoprotein that contains a 333 amino acid (aa) extracellular domain (ECD), two tandem transmembrane segments, and a second ECD of 15aa (1). Alternative splicing of human CRELD1 generates an additional isoform with a substitution that encompasses the transmembrane segments and the C-terminal ECD (1). CRELD1 is widely expressed during development and in the adult (1). It interacts with Reticulon 3/RTN3 and inhibits the pro-apoptotic activity of RTN3 (2). CRELD1 also associates with Adrenergic alpha1 receptors in the prostate and limits their expression (3). Missense mutations of human CRELD1 are associated with susceptibility to atrioventricular septal defects in the heart (4). Source: Recombinant protein corresponding to aa30-362, Gln30-Glu362, from human CRELD1, fused to his-tag at C-terminal, NS0-derived. Molecular Weight: ~50-55kD Endotoxin: <0.10EU/1ug (LAL method). Biological Activity: Measured by its ability to induce adhesion of ATDC5 mouse chondrogenic cells. The ED50 for this effect is 0.3-1.2ug/ml. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.